EurekAlert!

Metabolic control of inflammation uncovered: key enzyme turns off lung inflammation

Immunometabolism have advanced the understanding of dynamic interplay between metabolic pathways and immune responses.
The Scientist

Horizon Discovery extends CRISPR Screening Service to primary human T cells

Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to ...

CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
KLFY News 10

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of ...

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies ...
Nasdaq

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
GEN - Genetic Engineering and Biotechnology News

Patient Dies After Treatment with Intellia CRISPR Therapy in Phase III Trial

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...